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Abstract This study aimed at investigating the use of
psychosocial interventions and psychotropic co-medication
among stimulant-treated children with attention-deficit
hyperactivity disorder (ADHD) in relation to the presence
of psychiatric co-morbidity. Stimulant users younger than
16 years were identified in 115 pharmacies and a ques-
tionnaire was sent to their stimulant prescribing physician.
Of 773 questionnaires sent out, 556 were returned and were
suitable for analysis (72%). The results are based on 510
questionnaires concerning stimulant-treated children for
whom a diagnosis of ADHD was reported. Of the 510
children diagnosed with ADHD, 31% had also received
one or more other psychiatric diagnoses, mainly pervasive
developmental disorder or oppositional defiant disorder/
conduct disorder. We found an association between the
presence of co-morbidity and the use of psychosocial
interventions for the child (P \ 0.001) and the parents
(P \ 0.001). In the ADHD-only group, 26% did not
receive any form of additional interventions, while psy-
chosocial interventions varied from 8 to 18% in children
with ADHD and psychiatric co-morbidity. The presence of
diagnostic co-morbidity was also associated with the use of
psychotropic co-medication (overall, P = 0.012) and
antipsychotics (P \ 0.001). Stimulant-treated youths with
ADHD and psychiatric co-morbidity received more psy-
chosocial interventions and psychotropic co-medication
than children with ADHD-only. The type of psychosocial
interventions and psychotropic co-medication received by
the children and their parents, depended on the specific
co-morbid psychiatric disorder being present.
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Introduction
Stimulants are first-line drugs in the treatment of attention-
deficit hyperactivity disorder (ADHD) [2, 3]. The rapid
increase of stimulant use among children in the 90s [19, 20,
22, 27, 28, 33] has raised global concern about the use of
stimulants [1, 12, 19, 26, 27, 33]. One of the concerns is the
application of stimulant drugs without other forms of
treatment, especially since there has been increasing
awareness that many children with ADHD also have other
co-morbid psychiatric disorders that warrant special treat-
ment consideration [10, 14, 29]. Suggested treatment
options depend on the primary diagnosis and the presence
of co-morbidity. For instance, for children with ADHD and
co-morbid oppositional defiant or conduct disorder (ODD/
CD) symptoms, experts recommend a combination treat-
ment of psychostimulant medication and psychosocial
intervention such as parent management training and cog-
nitive behavioural therapy [14]. On the other hand, children
with impaired motor skills may benefit from psychostim-
ulant medication combined with treatment by an occupa-
tional or physiotherapist [10]. Until now, treatment of
ADHD with co-existing psychiatric disorders is guided
more by physicians’ experience than clinical trials, and
more trials should be undertaken [29].
The few studies examining treatment patterns among
children with ADHD and psychiatric co-morbidity origi-
nated from the USA. Two of these studies focused pri-
marily on psychotropic pharmacotherapy patterns. Among
a cohort children aged 5–12 years, Boles et al. found that
children with ADHD and psychiatric co-morbidity were
more likely to use a combination of psychostimulant and
other psychotropic medications than children with
uncomplicated ADHD (28 versus 12%) [4]. A comparable
result was found by Radigan et al. among a group of
3–19 year old children [21]. Children with ADHD and two
or more co-morbid psychiatric disorders more often used a
combination of stimulant and non-stimulant psychotropic
medication compared to children with ADHD-only or
ADHD and one disorder (37, 28, 19%, respectively).
Another study of Robison et al. examined the prevalence of
single and combination treatment modalities for children
aged 5–18 years with ADHD in relation to co-morbidity
[25]. They reported that children with ADHD without
co-morbidity were more likely to receive stimulant medi-
cation alone (51%) and less likely to receive additional psy-
chotherapy or mental health counselling (26%) compared
to all children with ADHD, with or without co-morbidity
(42 and 32%, respectively). Psychotropic co-medication
was not taken into account in this study.
We conducted a survey among physicians of a nation-
wide sample of stimulant-treated children in the Nether-
lands, to investigate the use of psychosocial interventions
and psychotropic co-medication among stimulant-treated
children with ADHD in relation to the presence of psy-
chiatric co-morbidity.
Methods
This research was a follow-up of a questionnaire survey
among parents of stimulant-treated children in 2003. To
obtain a nationwide community sample of stimulant-trea-
ted children irrespective of the prescribing physician,
pharmacies were used for detecting records of stimulant-
treated children in their pharmacy information system.
Since all prescriptions from medical doctors are entered in
the pharmacy information system, regardless of particular
health insurance or reimbursement status of the medication,
the pharmacy is a reliable source of detecting medication
users [15].
In the first 3 weeks of May 2003, 115 pharmacies
located all over the Netherlands identified current users of
methylphenidate and dexamphetamine in their information
system and sent a questionnaire to their carer. Current users
were defined as children younger than 16 years for whom
at least two stimulant prescriptions were dispensed
between 1 November 2002 and 1 May 2003, of which at
least one prescription was in 2003.
The findings of the parents’ questionnaire and the
response analysis were subject of another study and were
published elsewhere [8, 9]. For the present study, it was
important that the parents’ questionnaire included a request
for an informed consent to approach the stimulant pre-
scribing physician. Informed consent was needed from the
parents, and also from children if aged 12 years and older.
After informed consent was received, a questionnaire and a
copy of the informed consent were sent to the physician
currently prescribing stimulants for the child. The protocol
was approved by the Medical Ethics Board of the Uni-
versity Medical Centre in Groningen.
Questionnaire
The questionnaire was tested among five physicians. The
resulting questionnaire contained open-ended and multiple
choice questions about stimulant treatment, psychiatric
diagnoses, co-medication and several types of non-phar-
macological psychosocial interventions focused at the child
and/or the parents. Only psychosocial interventions deliv-
ered by specifically trained mental health professionals
(e.g. psychologists, psychiatrists, psychotherapists, social
workers) were included. Psychosocial interventions
directly aimed at the child, such as individual or group-
based cognitive behavioural therapy, social skills and
self-regulation training, were classified as child-focused
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interventions. Training which took a maximum of 2 h per
week was classified as non-intensive, whereas intensive
treatment programs took more than 2 h per week. Physio-
therapy implied physical exercises for motor problems and
all dietary interventions (e.g. elimination diet) were clas-
sified under ‘‘diet.’’ Treatment for children admitted to a
hospital or residential centre for mental disorders was
defined as inpatient treatment. Treatment for children
attending day hospital programs was defined as day treat-
ment. Special education services were limited to children
who attend specialized schools. Common and simple
interventions at regular schools that do not require medical
consultation, such as altered seating and home-school-
notes were not qualified as psychosocial interventions in
this study. Interventions aimed at parents to teach them
specialized child-management techniques were classified
as parent-focused interventions. Individual parent training
or group-based parent training was distinguished. Home
training is an intensive form of family training in the home
setting, sometimes with the use of video recording. Other
forms of therapy or courses for parents were classified as
‘‘other training/course.’’
Analysis
Questionnaires were regarded unsuitable for analysis if the
questionnaires were returned blank or when the physician
reported not being the prescriber. Children were classified
based on their diagnosis as reported by their physician.
Only children diagnosed with ADHD were included in the
present study. When no other diagnosis was reported, the
children were classified as ‘‘ADHD-only’’, when pervasive
developmental disorder (autistic disorder or PDD-NOS)
was reported as ‘‘ADHD ? PDD’’, when one of these
disruptive behaviour disorders was reported as ‘‘ADHD ?
ODD/CD’’, and when one or more psychiatric diagnoses
other than PDD and ODD/CD were reported they were
classified as ‘‘ADHD ? other co-morbidity.’’ Children
with ADHD and both PDD and ODD/CD were excluded
from the analysis.
We compared child characteristics and the use of psy-
chosocial interventions and psychotropic co-medication in
the four diagnostic groups. Omnibus tests were used to test
whether the proportions in the four diagnostic groups dif-
fered significantly across each group. Significant Chi-
square tests were followed by post hoc comparisons: (1)
ADHD-only versus ADHD ? PDD, (2) ADHD-only ver-
sus ADHD ? ODD/CD, (3) ADHD-only versus ADHD ?
other co-morbidity, (4) ADHD ? PDD versus ADHD ?
ODD/CD, (5) ADHD ? PDD versus ADHD ? other
co-morbidity, (6) ADHD ? ODD/CD versus ADHD ? other
co-morbidity. In general, a P-value \0.05 was considered
statistically significant. To adjust for multiple comparisons,
post hoc tests were considered significant at P \ 0.01. All
analyses were performed using SPSS 11.0.
Results
The 115 pharmacies sent 1,307 questionnaires to parents of
stimulant users. Of these, 924 questionnaires (71%) were
returned. In 811 of the 924 cases (88%) permission was
given to approach the physician, of which 773 contained a
valid address. Of the 773 questionnaires sent to physicians,
556 questionnaires were returned (72%). According to the
physicians, 512 of the 556 children (92%) were diagnosed
with ADHD. Two subjects were diagnosed with ADHD
and both PDD and ODD/CD, leaving 510 cases for the
present study. Almost half of these questionnaires were
filled out by general practitioners (GPs, 47%). Child psy-
chiatrists and paediatricians were responsible for, respec-
tively, 27 and 23%. The mean age of the stimulant-treated
children with ADHD in this study was 10.5 years, and the
male-to-female ratio was approximately 5.7:1.
Co-morbidity
Of the 510 stimulant-treated children with ADHD, the
physician reported only the diagnosis of ADHD in 69%.
For the remaining children, the most frequently reported
co-morbidities were PDD (53 children, 10.4%), ODD/CD
(50 children, 9.8%), followed by learning disorder (28
children, 5.5%), mental retardation (22 children, 4.3%), tic
disorder (10 children, 2.0%) and anxiety disorder (5 chil-
dren, 1.0%). Of the 53 children in the PDD group, 49 were
diagnosed PDD-NOS and 4 with autistic disorder. Of the
50 children in the ADHD ? ODD/CD group, 48 children
were diagnosed with ODD and 5 with CD; 3 children were
reported to have both ODD and CD. For 57 children (11%)
co-morbidity other than PDD or ODD/CD was reported.
Type of prescriber
The type of physician prescribing stimulants was associated
with the presence of co-morbidity (P \ 0.001). Of the
children with ADHD and a co-morbid disorder, 35%
received their current stimulant prescriptions from a child
psychiatrist, which was almost twice the percentage com-
pared to children with ADHD-only. Stimulant prescriptions
for children with ADHD-only were mostly provided by
GPs. In 41% of the children with ADHD-only, stimulant
prescribing was transferred from a child psychiatrist or
paediatrician to a GP after initiation of treatment. For
children with co-morbid PDD, ODD/CD or another psy-
chiatric disorder this percentage was lower: 30, 18 and 23%,
respectively (P \ 0.01, data not shown). No relationship
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was found between the presence of co-morbidity and age,
gender and time since the first dispensed stimulant pre-
scription was filled (P C 0.42).
Additional interventions
Overall, there is an association between the presence or
absence of co-morbidity and attending a specialized school
(Table 1). Sixty percent of the children with ADHD and
co-morbid PDD were reported to attend a specialized
school. This was twice as often compared to children with
ADHD-only.
The presence or absence of co-morbidity was also asso-
ciated with the use of psychosocial interventions aimed at the
child (Table 2). Stimulant-treated children with ADHD and
co-morbid PDD, ODD/CD or other psychiatric co-morbidity
were reported to receive more psychosocial interventions
aimed at the child than children with ADHD-only.
Children with ADHD and co-morbid PDD or co-morbid
ODD/CD received intensive training, day treatment and
treatment in an inpatient clinic more frequently than chil-
dren with ADHD-only.
The presence of psychiatric co-morbidity was also
associated with parent-focused interventions (Table 2).
Parent-focused interventions were most frequently offered
to parents of children with ADHD ? PDD (89%) or ODD/
CD (84%). Home training was provided when a PDD
diagnosis was present in almost a quarter of these families,
almost three times more often compared to families of a
child with ADHD-only. Of the children in the ADHD-only
group, 26% did not receive any psychosocial interventions
focused at the child or parents (data not shown). This
percentage was only 18 in the ADHD ? other co-mor-
bidity group, 10 in the ADHD ? ODD/CD group and 8 in
the ADHD ? PDD group.
Psychotropic co-medication
There is an association between presence or absence of
co-morbidity and the use of psychotropic co-medication
(Table 2). Use of psychotropic co-medication was most
prevalent among stimulant-treated children with ADHD ?
PDD (36%), which was significantly more frequent com-
pared to children in the ADHD-only group (18%). Anti-
psychotic use was the most prevalent co-medication among
stimulant-treated children with ADHD ? PDD (17%).
This was almost sixfold higher than in the ADHD-only
group (3%).
The frequency of melatonin use did not differ signifi-
cantly between the groups. Clonidine, antiepileptics, anti-
depressants, and hypnotics/anxiolytics were not frequently
used as co-medication.
Discussion
This study among showed that stimulant-treated children
with ADHD and co-morbid psychiatric disorders received
Table 1 Characteristics of stimulant-treated children diagnosed with ADHD-only, ADHD with PDD, ADHD with ODD/CD and ADHD with
other psychiatric co-morbidity
ADHD-only ADHD ? co-morbidity v2 test
n = 350 ADHD ? PDD
(n = 53)
ADHD ? ODD/CD
(n = 50)
ADHD ? other
co-morbidity (n = 57)
n n n n P
Age (mean years) 350 (10.5) 53 (10.6) 50 (10.3) 57 (10.4) 0.94
Male (%) 300 (86) 44 (83) 44 (88) 46 (81) 0.69
Specialized school (%) 98 (28b) 32 (60a) 20 (40ab) 25 (44ab) \0.001
Time since first prescription
\1 year (%) 78 (22) 8 (15) 8 (16) 15 (26) 0.42
1–2 years (%) 64 (18) 10 (19) 14 (28) 12 (21)
[2 years (%) 203 (58) 33 (62) 26 (52) 30 (53)
Unknown (%) 5 (1) 2 (4) 2 (4) 0 (0)
Current prescriber stimulants
GP (%) 190 (54a) 18 (34b) 13 (26b) 15 (26b) \0.001
Paediatrician (%) 79 (23) 13 (25) 8 (16) 18 (32)
Child psychiatrist (%) 69 (20) 22 (42) 28 (56) 20 (35)
Other (%) 9 (3) 0 (0) 1 (2) 4 (7)
Unknown (%) 3 (1) 0 (0) 0 (0) 0 (0)
Proportions that share the same superscript are not significantly different from each other
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more additional psychosocial interventions and co-medi-
cation than children with an ADHD diagnosis only. The
type of psychotropic co-medication and interventions
received depended on the type of co-morbid disorder.
Co-morbidity
For 31% of cases psychiatric co-morbidity was reported in
this sample of stimulant-treated children with ADHD. Other
studies reported higher co-morbidity percentages ranging
from 44% in community-derived samples to 87% in clini-
cally-referred children diagnosed with ADHD [18]. In
particular, the presence of ODD/CD in our study (10%) was
very low compared to, e.g. the 50–60% reported by Gillberg
[10]. Our low co-morbidity figures may be explained by a
number of phenomena. First, low co-morbidity figures may
be explained by under-diagnosis of psychiatric disorders
because not all children were thoroughly screened by child
psychiatrists. Second, may be physicians were not inclined
to report diagnoses that do not support the prescription of
stimulants since stimulant use was the entry point for this
study. In particular, when the current prescriber was a GP it
is likely that the first prescriber was a specialist. When the
communication between the GP and specialist was less than
ideal, the patient’s medical record in the GPs documenta-
tion could be incomplete.
Pervasive developmental disorder as the most frequently
mentioned co-morbid disorder, warrants special attention.
Within the DSM-IV classification system, ADHD and PDD
are exclusionary diagnoses, and therefore it is impossible to
give a PDD and an ADHD classification to the same
patient. There has been increasing debate about this issue
[6, 11, 16, 23, 31]. The general point of the critics of the
exclusionary criterion is that the overlap in clinical
symptoms between ADHD and PDD is evident in practice,
and removing the exclusionary criteria may be beneficial
for stimulating research and optimizing treatment in these
children [16, 23, 31]. It seems that many clinicians in the
Netherlands have dropped the DSM-IV exclusionary cri-
terion in clinical practice.
Table 2 Characteristics of additional interventions and psychotropic co-medication among stimulant-treated children diagnosed with ADHD-
only, ADHD with PDD, ADHD with ODD/CD and ADHD with other psychiatric co-morbidity
ADHD-only ADHD ? co-morbidity v2 test
n = 350 ADHD ? PDD (n = 53) ADHD ? ODD/CD (n = 50) ADHD ? other
co-morbidity (n = 57)
n % n % n % n % P
Psychosocial interventions
Child-focused interventions—any 189 54b 41 77a 37 74a 42 74a \0.001
Non-intensive training 108 31 13 25 17 34 18 32 0.27
Physiotherapy 62 18 16 30 10 20 18 32 0.12
Diet 15 4 6 11 1 2 1 2 –
Intensive training 27 8b 17 32a 14 28a 4 7b \0.001
Day treatment 22 6b 16 30a 11 22a 7 12ab \0.001
Inpatient treatment 11 3b 9 17a 11 22a 3 5ab \0.001
Parent-focused interventions—any 223 64c 47 89a 42 84ab 36 63bc \0.001
Individual parent training 193 55b 41 77a 40 80a 34 60ab \0.01
Group based parent training 29 8 9 17 7 14 1 2 –
Home training 28 8b 12 23a 5 10ab 4 7ab \0.01
Other training/course 26 7 5 9 6 12 8 14 0.10
Psychotropic co-medication
Any 63 18b 19 36a 14 28ab 10 18ab 0.012
Melatonin 41 12 7 13 8 16 4 7 0.49
Antipsychotics 11 3b 9 17a 5 10ab 5 9ab \0.001
Clonidine 7 2 2 4 0 0 0 0 –
Antiepileptics 3 1 2 4 1 2 1 2 –
Antidepressants 1 0 1 2 0 0 0 0 –
Hypnotics/anxiolytics 1 0 0 0 0 0 0 0 –
Proportions that share the same superscript are not significantly different from each other
– Denotes Chi-square not valid due to small numbers
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Type of prescriber
In the Netherlands, a GP often takes over responsibility for
prescribing medication which was initiated by a specialist.
We found this was most frequently true for prescribing
stimulant medication for children with ADHD-only.
However, the majority of the children with psychiatric
co-morbidity still received their stimulant prescriptions
from a specialist, even in case of children who had been
using stimulants for over 2 years. This difference may be
explained by the fact that in more complicated cases the
specialist remains closely involved with the child’s treat-
ment after its initiation.
Additional interventions
In this study, stimulant-treated children with ADHD and
co-morbidity and their parents received considerably more
treatment modalities than children with ADHD-only.
Similar findings have been reported on the basis of US
studies [4, 21]. Most guidelines recommend the combina-
tion of pharmacological and psychosocial interventions [2,
3, 14, 29]. This is supported by evidence from the MTA
study, reporting a somewhat higher efficacy of multimodal
interventions in case of ADHD and co-morbid disorders
[13, 30]. However, a substantial proportion of the children
in our study did not receive additional interventions. It may
be that many children with ADHD without co-morbidity
and even some children with co-morbidity respond ade-
quately to pharmacological treatment only. However, it is
not unlikely that some children receive less than optimal
care. This is aggravated by our finding that almost 20% of
the stimulant-treated youths were not monitored [9], so in
those cases the treatment outcome is unknown to the
clinician.
Psychotropic co-medication
We found an association between the presence of psychi-
atric co-morbidity and the use of psychotropic co-medi-
cation among stimulant-treated children with ADHD. This
is in line with the few earlier reports from the USA [4, 21].
However, Radigan et al. reported an increased use of alpha
agonists, antipsychotics, antidepressants, antiepileptics and
anxiolytics among Medicaid children with ADHD and a
co-morbid psychiatric disorder [21], while we found only
an increased use of antipsychotics among children with
ADHD and co-morbid PDD. Part of this difference may be
explained by different prescribing practices in the USA and
the Netherlands.
The more frequent use of antipsychotics among children
with ADHD and PDD may be understood as confirmation
that the presence of PDD symptoms in children with
ADHD has practical implications for treatment. After all,
several studies have reported a positive effect of antipsy-
chotics in reducing aggressive behaviour in children with
PDD and disruptive behaviour disorders [5, 7, 24]. In
contrast to reports from the USA, we found antipsychotics
to be the most prevalent co-medication instead of anti-
depressants. In our study, co-medication with antidepres-
sants was reported in less than 2%, compared to 4–7% in
the USA [17, 20, 32]. This lower use of anti-depressants
may be partly explained by differences in timing of the
study periods, but is probably more likely to be explained
by cross cultural differences in medical practice, including
the attention paid to internalizing versus externalizing
disorders.
Limitations
Children with ADHD who did not receive stimulants were
not included in our study and therefore the findings of our
study cannot be generalized to all children with ADHD.
Another limitation of our study is that no information was
available on how children were assessed, so no statements
could be made about the appropriateness or the relative
weight of the diagnoses.
Our two-step recruitment procedure implied that phy-
sicians could only be approached if the responding parents
and their child gave their consent, which may have led to
selection bias. No association was found between giving
consent and the child’s age, gender or the type of pre-
scribing physician, but physician response rate differed
significantly for the type of prescribing physician, being
highest for paediatricians (83%) and lowest for child psy-
chiatrists (62%) [8].
Physicians were the only information source in this
study. This may possibly have resulted in an underesti-
mation of psychosocial interventions, because physicians
may not be aware of all interventions in non-medical
settings, for example at school. However, in the Nether-
lands mental health interventions are not delivered
through the school system like in the USA. Individual
children can receive didactic interventions such as reme-
dial teaching within the school system, but individualized
behaviour management programs are not available on
regular schools or are always part of an elaborate
behaviour management program put in place through
health care professionals, with teachers as ‘‘co therapists.’’
Using the current prescriber of stimulant medication as
the only information source also may have lead to
information bias. GPs taking over prescribing responsi-
bility may have less information and knowledge about
psychosocial interventions than psychiatrists or paediatri-
cians. This may have resulted in an underestimation of
interventions mentioned by GPs.
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Conclusion
Multimodal treatment of youth with ADHD is a common
medical practice in the Netherlands, particularly for youth
with co-morbid psychiatric disorders. Whether this reflects
what is known about the effectiveness of multimodal
interventions for children with ADHD and co-morbidity
and their parents is unknown and might be subject for
further research. The use of psychotropic co-medication for
youth has led to some concerns, specifically about the
safety of combining stimulants with antipsychotics for
children diagnosed with ADHD and PDD.
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